The association of proton pump inhibitors and inflammatory bowel disease from the perspective of gut microbiota perturbation
Abstract
Inflammatory bowel disease (IBD) is closely related to changes in the gut microbiota, with proton pump inhibitors (PPIs) possibly playing a role. PPIs use is associated with altering gut microbiota and potentially influencing IBD onset and progression. This review explores the mechanisms by which PPIs affect gut microbiota and IBD, suggests strategies to mitigate dysbiosis, outlook on the causal relationship validation between PPIs use and IBD risk, emphasizing the broader impact of acid suppressants on gut health.
Read the paper
Related studies
- Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.